INTRODUCTION
============

Attention deficit/hyperactivity disorder (ADHD) is one of the most common child psychiatric disorders and is characterized by symptoms of inattention, hyperactivity, and impulsivity ([@bib2]). Because of their efficacy, pharmacological treatments using stimulant medications, such as methylphenidate, have typically been the primary treatment for ADHD. However, in recent years there has been a growing interest in nonpharmacological treatments to provide an alternative for parents and clinicians looking for alternative or additive treatments.

One popular nonpharmacological treatment for ADHD is dietary supplementation using long-chain omega-3 polyunsaturated fatty acids (LC-PUFAs). However, there has been a fair amount of debate on the efficacy of this treatment. Two early studies reported a significant reduction of ADHD symptoms in healthy children after supplementation with the omega-3 PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) ([@bib35]; [@bib39]). However, a later attempt to replicate these findings in a group of children diagnosed with ADHD failed to find such effects ([@bib23]). In fact, even though reduced plasma omega-3 PUFA levels have been reported in children and adolescents with ADHD ([@bib3]; [@bib9]; [@bib11]; [@bib12]; [@bib41]), to date most intervention studies investigating the efficacy of omega-3 PUFAs to reduce ADHD symptoms have yielded conflicting or negative results ([@bib7]; [@bib13]; [@bib20]; [@bib21]; [@bib34]; [@bib36]; [@bib42]; [@bib44]; [@bib47]).

Recently however, two independent meta-analyses provided new evidence for possible beneficial effects of omega-3 PUFA supplementation on symptoms of ADHD with small but positive effect sizes between 0.14 ([@bib40]) and 0.31 ([@bib8]). Furthermore, an open-label, exploratory study by [@bib4]) showed clinical benefits of treatment with omega-3 PUFA supplements in addition to methylphenidate (MPH) over treatment with MPH alone in children with ADHD.

The neurobiological mechanism underlying an effect of omega-3 supplementation is far from clear. Omega-3 PUFAs are thought to play an important role in cell membrane elasticity and myelination and may thus affect neural signal transduction ([@bib6]). Animal studies indicated that omega-3 PUFA deficiency, and specifically DHA deficiency, results in decreased neuron size in rats that were raised on a DHA-deficient diet ([@bib1]). Furthermore, both dopaminergic and serotonergic neurotransmission have been shown to be reduced in rats on an omega-3 PUFA-deficient diet ([@bib10]; [@bib49], [@bib50]), with marked effects in the frontal cortex. Specifically, lower frontal cortical omega-3 PUFA status correlated with hyperactive and impulsive behavior in rats ([@bib45]). Interestingly, a vast body of human literature has implied dopamine dysfunction and impairments in cognitive control in ADHD ([@bib15]; [@bib24]; [@bib43]). Taken all this together, this may suggest a potential target for omega-3 supplementation in the treatment of this disorder.

Therefore, we set out to investigate the effects of omega-3 PUFA dietary supplementation on ADHD symptoms in young boys with and without ADHD in a randomized, placebo-controlled trial. We included a typically developing reference group to investigate the specificity of treatment to subjects with ADHD. Our hypotheses were that dietary supplementation with omega-3 PUFAs would: improve symptoms of ADHD, increase phospholipid PUFA status as assessed by cheek cell phospholipid composition, and increase the rate of dopamine turnover as assessed by homovanillic acid (HVA) excretion in urine. Furthermore, we expected that dietary supplementation with omega-3 PUFAs would improve cognitive control in ADHD and that it would increase activation in the associated prefrontal and striatal areas, as assessed with fMRI.

MATERIALS AND METHODS
=====================

Participants
------------

The study was approved by the Ethics Committee of the University Medical Centre Utrecht, The Netherlands, and took into account the ethical principles for medical research involving human subjects as stated in the declaration of Helsinki (amendment of Washington, 2002). Written and oral information was provided, after which written informed consent was obtained from all parents. All children provided written assent.

A total of 40 boys between 8 and 14 years of age with a DSM-IV diagnosis of ADHD were recruited through the Department of Psychiatry at the University Medical Center in Utrecht, and through advertising. The clinical diagnosis was confirmed by a trained researcher using the Diagnostic Interview Schedule for Children--Parent Version (DISC-P). We chose to only include boys in this study as we wanted to minimize the number of potential confounds (such as gender) on brain activity, and ADHD is more prevalent in boys than girls. The children with ADHD were either medication naive or using psychostimulant medication (methylphenidate only). No other forms of psychoactive medication were accepted in this study ([Table 1](#tbl1){ref-type="table"}). Children with ADHD who were on stimulant medication were instructed not to take their medication for 24 h before the fMRI scan. However, children were allowed to use their medication throughout the intervention period (16 weeks). Medication continued to be managed by the outside provider (eg, general practitioner, pediatrician, or psychiatrist). Any changes in medication status were recorded on a monthly basis by the research team.

A total of 39 typically developing boys matched to the patients for age, hand preference, and body mass index (BMI; at inclusion) were recruited as a reference group (hereafter also referred to as RG) through advertising at primary and secondary schools in the wider Utrecht area, and from the pool of volunteers participating in studies by our lab.

All subjects were screened by telephone interview to check for major neurological or psychiatric disorders, as well as psychiatric diagnoses in subjects and their first-degree relatives. Parents of the typically developing subjects participated in a DISC-P interview with trained researchers to confirm the absence of any psychiatric conditions and their first-degree relatives. None of the typically developing subjects were using any form of psychoactive medication.

IQ was assessed for all participants using a four subtest short form of the Wechsler Intelligence Scale for Children (WISC-III; [@bib26]). As is often reported, children with ADHD had a slightly lower total IQ score than typically developing children ([Table 1](#tbl1){ref-type="table"}). As this is typical of the ADHD phenotype, IQ was not entered as a covariate in any of the designs to prevent partialling out variance that is potentially relevant to the disorder ([@bib14]; [@bib48]). Hand preference was assessed using the Edinburgh Handedness Inventory ([@bib31]). There were no significant differences in hand preference, nor were there any differences in age, parental education (measured in years), and BMI ([Table 1](#tbl1){ref-type="table"}).

Design
------

The 16-week intervention followed a double-blind randomized placebo-controlled design, where investigators, parents, and participants were all blind to the treatment conditions ([Figure 1](#fig1){ref-type="fig"}). The 2 × 2 factorial design included four groups: children with ADHD receiving either placebo or omega-3 fortified margarine (ADHD^Placebo^ and ADHD^Active^, respectively) and children from the reference group receiving the same treatment (RG^Placebo^ and RG^Active^). All participants were randomly assigned to one of the treatment conditions by a member of the Unilever Center for Nutritional Intervention Trials.

Intervention
------------

This trial was registered at clinicaltrials.gov under number NCT01554462. All participants were instructed to consume a daily dose of 10 g of either normal or omega-3 fortified margarine. The active product was full fat (80%) margarine, containing 650 mg DHA and 650 mg EPA per 10 g serving. The dose of the active ingredients DHA and EPA in the intervention product was under the US Generally Recognized As Safe (GRAS) level (FDA, 2004). The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (refined plant oils) instead of EPA and DHA; the total amount of saturated fatty acids and omega-6 fatty acid were matched in the placebo and active product (see [Supplementary Materials 1](#sup1){ref-type="supplementary-material"} for more details).

Compliance was assessed by weighing the leftover products that parents returned to the investigators on a monthly basis. Furthermore, participants and parents kept a calendar, on which daily margarine consumption was recorded. Participants were asked to maintain their usual diet throughout the intervention period, with the following constraints: they were not allowed to use other supplements containing omega-3 or foods fortified with EPA and DHA during the intervention, nor were they to consume fatty fish more than once a week. Compliance to these requirements was measured on a monthly basis using the Diet and Lifestyle Change Questionnaire (DLCQ).

Physiological and Behavioral Measures
-------------------------------------

During the baseline and follow-up visits, cheek cell samples were collected using cotton swabs for analysis of phospholipid fatty acid levels. This method was chosen over blood sampling in children, as it is not invasive. Analyses of fatty acids were performed by gas chromatography after phospholipid isolation by thin-layer chromatography as described previously ([@bib25]). Furthermore, urine samples were collected to measure the HVA to creatinine ratio, as a proxy for dopamine turnover. The Essential Fatty Acids Questionnaire (EFAQ) was collected to assess symptoms of FA deficiency (see [Supplement Materials 1](#sup1){ref-type="supplementary-material"} for methodological details).

Finally, the parent-rated Child Behavior Checklist (CBCL) and Strengths and Weaknesses of ADHD symptoms and Normal behavior scale (SWAN) were collected for all participants, both of which measure the severity of ADHD symptoms (see [Figure 1](#fig1){ref-type="fig"}). The CBCL (collected twice) was used as the primary outcome measure, whereas the SWAN (collected five times) was used to measure change over time. In addition to the parent-rated questionnaires, the Teacher Report Form (TRF) was sent out to classroom teachers or mentors of the participants at baseline and follow-up. However, the response rate for this instrument was very low (54 of 79 returned at baseline, 31 of 76 at follow-up), and we had to exclude these data from further analysis.

fMRI Acquisition and Analysis
-----------------------------

The fMRI study included a traditional Go-NoGo paradigm that has been described in previous work ([@bib18], [@bib16], [@bib17]). Standard preprocessing was performed in SPM8 (Wellcome Department of Cognitive Neurology, [www.fil.ion.ucl.ac.uk](http://www.fil.ion.ucl.ac.uk)). MRI scans were excluded if head motion exceeded 3 mm or the size of one voxel at baseline and/or follow-up. Hence, 13 children with ADHD and 6 typically developing children were excluded from the SPM fMRI analysis. For a full description of the first- and second-level analysis of the fMRI study, please see [Supplementary Material 2](#sup1){ref-type="supplementary-material"}.

Statistics
----------

All statistical analyses on the demographic, behavioral, and physiological measures were performed with the SPSS statistical package 20.0 (SPSS, Chicago, IL). Group differences on the demographic variables were analyzed using *χ*^2^, independent samples *t*-tests, or Mann--Whitney *U*-tests, as appropriate.

For the behavioral and physiological measures, independent samples *t*-tests or Mann--Whitney *U*-tests were used to analyze group differences at baseline between the diagnostic groups, and between the intervention groups. To investigate treatment effects, all variables of interest were fed into an ANCOVA (analysis of covariance) model with the baseline measurement entered as a covariate ([@bib46]). Intention-to-treat (ITT) analyses, including all subjects randomized into the trial, were performed using a linear mixed effects (LME) model with restricted maximum likelihood (REML) estimation where diagnostic status and treatment condition were included as fixed factors. Mean adjusted difference (MAD) and 95% confidence intervals (CIs) were also calculated.

Initially, age included as a covariate in the analyses. However, it did not correlate with any of the measures of interest, and as such it was excluded from the final models. Significant findings were further analyzed using paired or independent samples *t*-tests. Pearson\'s correlations were performed to analyze the relationship between behavioral and physiological measures. Finally, a *post hoc* power analysis was conducted to determine the retrospective power of the study.

RESULTS
=======

After inclusion, 77 children successfully completed the study and participated in both fMRI sessions. One RG^placebo^ participant dropped out after 3 months for personal reasons. One RG^active^ participant dropped out after developing a skin rash that later turned out to be unrelated to the test product. After dropping out of the study, the parents of this second participant were notified about the contents of the test product by an independent member of Unilever Center for Nutritional Intervention Trial. The researchers remained blind throughout the whole study period. Compliance was considered acceptable if two-thirds of the test product was consumed during the intervention period, with no periods of nonconsumption longer than 7 days (eg, because of illness). One participant in the ADHD^placebo^ group did not meet these criteria, and was excluded from the analyses. There were no differences in compliance between the four treatment groups (*χ*^*2*^= 2.733, *p*=0.435, [Table 1](#tbl1){ref-type="table"}).

Behavioral Results
------------------

At baseline, subjects with ADHD scored higher than the reference group on the CBCL subscales Attention Problems (*p*\<0.001, see [Table 2](#tbl2){ref-type="table"}), Rule Breaking Behavior (*p*\<0.001), and Aggressive Behavior (*p*\<0.001). CBCL scores did not correlate with age in either diagnostic group. Completer analyses by means of ANCOVA showed a main effect of diagnostic status (F(1, 67)=6.92, *p*=0.011) at follow-up, where children with ADHD scored higher on CBCL attention problems. ANCOVA further showed a main effect of treatment condition, where after supplementation with omega-3 PUFAs, scores on CBCL attention problems were reduced in comparison with supplementation with placebo ([Figure 2a](#fig2){ref-type="fig"}: F(1, 67)=14.99, *p*\<0.001). Although there was no interaction between diagnostic status and treatment condition, it should be noted that the typically developing group receiving active treatment did not show a significant reduction in attention problems. The ITT analysis using the LME model yielded similar results for CBCL attention problems showing a significant effect of diagnostic status (MAD=6.37, 95% CI 8.31--4.42), *t*(90)=6.51, *p*\<0.001) and an interaction effect between treatment condition and time (MAD=−1.83, 95% CI (−2.91 to −0.76), *t*(67)=3.42, *p*=0.001). There were no significant effects of treatment on the CBCL Rule Breaking and Aggressive Behavior subscales, or on the SWAN questionnaire.

Three children in the ADHD^Active^ group and four children in the ADHD^Placebo^ group reported that the dosage of their stimulant medication had been increased during the intervention period. The treatment effect on the Attention Problems subscale was still found in a reanalysis of the CBCL data excluding these participants (ANCOVA: F(1, 61)=14.22, *p*\<0.001, LME: MAD=−1.91, 95% CI (−3.10 to −0.77), *t*(60)=3.34, *p*=0.001).

Physiological Results
---------------------

Scores on the EFAQ ([Table 2](#tbl2){ref-type="table"}) were normalized by square root transformation. At baseline, there was a difference between children with ADHD and children in the reference group on the EFAQ (*t*(75)=2.72, *p*=0.008), where children with ADHD scored higher on symptoms of FA deficiency. However, only four children met cutoff criteria for FA deficiency (3 children with ADHD and 1 RG). There was no significant effect of supplementation with omega-3 PUFAs on the EFAQ, neither for subjects with ADHD nor the RG.

Analysis of the square-root transformed cheek cell phospholipids showed no differences between the four groups at baseline (F(3, 69)=1.92, *p*=0.135). At follow-up, there was a main effect of treatment (F(1, 63)=13.03, *p*=0.001), where %DHA in phospholipids was higher after supplementation with omega-3 PUFAs in comparison with supplementation with the placebo product (see [Figure 2b](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). The ITT analysis accounted for missing data at either baseline (6 samples) or follow-up (8 samples) and similarly showed an interaction between treatment condition and time (MAD=0.34, 95% CI (0.14--0.53), *t*(72)=3.47, *p*=0.001). For some samples, the amount of cheek cell phospholipids was too low to assess DHA levels reliably, leading to floor values of 0 for a number of samples (24 at baseline and 21 at follow-up). Reanalysis without these samples showed the same effect (ANCOVA: F(1, 29)=8.00, *p*=0.009), LME: MAD=0.28, 95% CI (0.12--0.44), *t*(51)=3.48, *p*=0.001). However, these results should be interpreted with caution, as cheek cell fatty acid data were below detection threshold for some subjects and missing for others.

Follow-up Pearson\'s correlation analyses showed that at baseline CBCL attention problems correlated negatively with omega-3 LC-PUFA status in the group of children with ADHD as a whole (*r*=−0.47, *p*=0.048; see [Figure 3a](#fig3){ref-type="fig"}), but not in children in the reference group (*r*=0.28, *p*=0.166). The correlation in the ADHD group persisted at follow-up (*r*=−0.48, *p*=0.042; see [Figure 3b](#fig3){ref-type="fig"}).

The data on the HVA to creatinine ratio were normalized using a natural logarithm. At baseline, the difference in the HVA ratio (μmol/mmol creatinine) approached significance (*t*(72)=1.92, *p*=0.059), with subjects with ADHD having slightly higher levels of this ratio than the reference group. No effects of the intervention were found on these measures, including in analyses with age or BMI included as covariates in the design.

fMRI Task
---------

Results typical of this task were found ([@bib18], [@bib16]); see [Supplementary Materials 2 and 3](#sup1){ref-type="supplementary-material"} for a detailed description of the fMRI results. There was no effect of dietary omega-3 supplementation on task performance or brain activation during the cognitive control task.

DISCUSSION
==========

Omega-3 PUFA dietary supplementation improved symptoms of inattention in boys with and without ADHD in a double-blind randomized controlled trial. This effect did not appear to be mediated by dopaminergic cognitive control networks, as measures of dopamine turnover and neural activity during cognitive control were unaffected by the intervention.

At baseline, boys with ADHD had higher symptoms of inattention than typically developing boys. Furthermore, there was an effect of treatment on parent-rated symptoms of ADHD, regardless of diagnosis. This effect was driven by the measures of inattention at follow-up: subjects who had received omega-3 PUFAs had lower scores on the CBCL attention problems subscale than subjects on placebo. This ties in with earlier studies that have suggested that omega-3 PUFA supplementation improves symptoms of inattention specifically, and not symptoms of ADHD more generally ([@bib20]; [@bib35]; [@bib39]). In line with recent meta-analyses ([@bib8]; [@bib40]), our results suggest that supplementation with omega-3 PUFAs may be beneficial in ADHD.

Moreover, our results indicate that typically developing children also benefit, showing the importance of omega-3 PUFA intake during development in general ([@bib19]; [@bib38]). Previous studies using sustained attention tasks have shown that dietary supplementation of omega-3 PUFAs leads to increases in brain activation in prefrontal areas and improved task performance in both children with ADHD and typically developing children ([@bib5]; [@bib27]; [@bib28]; [@bib44]). We used a cognitive control task and found no changes in brain activity or task performance after supplementation. Furthermore, dopamine turnover did not appear to be affected by the supplementation, as HVA levels in urine were not affected. Therefore, it appears that the neural mechanism underlying improvements in attention did not involve dopaminergic cognitive control networks.

The dietary intervention affected omega-3 PUFA levels in cheek cell phospholipids, as the level of DHA was significantly higher at follow-up for subjects who had been treated with the active product than for those who had received placebo. This observation was supported by the returned margarine tubs and diaries, and showed that the intervention was effective. Furthermore, in subjects with ADHD, higher levels of DHA were associated with lower attention problems, both at baseline and follow-up. The detected increase in DHA levels was more modest than in earlier studies where DHA was measured in plasma or erythrocytes ([@bib30]; [@bib32]). Cheek cell samples are more prone to contamination than blood samples and this may have contributed to this difference. An alternative explanation may be that the intervention was less effective than expected.

Most studies to date have suggested that omega-3 supplementation is effective through higher levels of EPA as opposed to DHA ([@bib8]; [@bib20]). The biological mechanism through which DHA acts on human brain function is not clear, even though this fatty acid is abundantly present in the brain\'s phospholipid membranes ([@bib6]; [@bib22]). As biosynthesis of DHA from its precursors *α*-linolenic acid and EPA is very low, a notable increase in DHA plasma level can only be accomplished through direct DHA intake ([@bib33]). Many of the omega-3 supplements used in previous studies, with often negative results, contained a relatively low DHA to EPA ratio, possibly obscuring direct effects of DHA. However, a recent H-MRS study by [@bib28]) showed that higher erythrocyte DHA levels were related to a better performance on a sustained attention task and ACC metabolic function in typically developing children. The results from previous work combined with the current study suggest that the combined supplementation with EPA and DHA accounts for the treatment effect in the present study and may thus yield the greatest improvements in behavior.

Although evidence of a moderate effect of dietary omega-3 PUFA supplementation is converging, it is unlikely that it will ever achieve the same behavioral improvements as stimulant medication in ADHD, with effect sizes ranging from 0.54 to 0.78 ([@bib37]). However, it is noteworthy that in the present study the majority of children with ADHD received the omega-3 PUFA supplements in addition to their regular medication. The behavioral improvement persisted even when changes in medication were taken into account in the analyses. This suggests that omega-3 PUFAs may be useful as an augmentation to standard pharmacological therapies. Indeed, recent reports showed that children receiving a combination of MPH and omega-3 PUFAs needed lower doses of MPH compared with children only receiving MPH to achieve the same clinical benefits ([@bib4]; [@bib29]).

Obvious strengths of our study include the randomized placebo-controlled double-blind design and the inclusion of a typically developing reference group to assess whether effects were specific to ADHD. However, there are also some limitations that should be taken into consideration. The first limitation is that in some subjects the quality of the cheek cell samples did not permit a reliable detection of DHA. However, this did not affect our statistical analyses negatively, as the effect of the dietary intervention reached statistical significance even without these values included. Phospholipid values did not show the expected extent of separation between placebo and intervention groups. However, these measures did differ between the active product and placebo intervention groups, and correlated with behavioral outcomes. A second limitation is that a small number of participants with ADHD had changes made to their medication during the intervention. However, reanalysis without these participants showed that the effect of the intervention still held without these subjects. Finally, sample sizes in the fMRI study were smaller than in the main study as a result of subject motion. However, the remaining sample was well matched and yielded only a tiny effect size of the intervention on MR signal. We conducted a *post hoc* power analysis to investigate what sample size would be necessary to show an effect of the intervention on brain activity, if this was indeed a real effect. The results of this power analysis indicated that only a huge sample size (*N*=718) would have shown a significant effect of treatment and suggests therefore that the nonsignificant differences in this study are most likely attributable to noise. Taken together, the absence of a treatment effect on the brain activity during a cognitive control task, on performance of the task, and on dopamine turnover suggest that the effect of the intervention on ADHD symptoms is unlikely to be mediated by dopamine systems.

In conclusion, this study provides new evidence that dietary supplementation using omega-3 PUFAs may be an effective augmentation of pharmacological treatments of ADHD. This effect does not appear to be mediated by dopaminergic cognitive control networks, but may involve other systems implicated in ADHD, such as attention networks.
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![Trial design. Schematic overview of the design of this double-blind randomized placebo-controlled trial, including all measures that were collected and the number of participants that were included at baseline. After 1, 2, and 3 months, interim visits took place during which compliance and behavior were measured. ADHD, attention deficit/hyperactivity disorder; CBCL, Child Behavior Checklist; DLCQ, Diet and Lifestyle Change Questionnaire; EFAQ, Essential Fatty Acids Questionnaire; SWAN, Strengths and Weaknesses of ADHD symptoms and Normal behavior scale; RG, reference group of typically developing children.](npp201573f1){#fig1}

![Main effect of omega-3 PUFA supplementation. (a) The mean difference between baseline and follow-up CBCL attention problems in both diagnostic groups, with main effects of diagnosis and the intervention. (b) The mean difference between baseline and follow-up square-root transformed %DHA levels as collected from cheek cell samples, with similar main effects. The asterisks denote significance at *p*\<0.01. ADHD, attention deficit/hyperactivity disorder; CBCL, Child Behavior Checklist; DHA, docosahexaenoic acid; RG, reference group of typically developing children.](npp201573f2){#fig2}

![The relation between omega-3 fatty acids and attention problems in ADHD, at baseline and at follow-up. (a) Correlation at baseline between square-root transformed %DHA and CBCL attention problems in children with ADHD (*r*=−0.47). (b) The same correlation at follow-up (*r*=−0.48). There was no correlation between %DHA and CBCL attention problems in typically developing children. ADHD, attention deficit/hyperactivity disorder; CBCL, Child Behavior Checklist; DHA, docosahexaenoic acid.](npp201573f3){#fig3}

###### Demographic Data and Compliance

                                                                  **ADHD, *N*=40**         **RG, *N*=39**      ***P-*value**
  ------------------------------ ----------------------------- ----------------------- ----------------------- ---------------
  *General*                                                                                                    
   Age                           Mean±SD (range)                10.3±2.0 (8.0--15.0)    10.9±2.0 (8.2--15.1)   0.163
   Total IQ                      Mean±SD (range)                104.3±16.2 (76--144)    113.6±17.4 (75--145)   0.017
   Parental Education in years   Mean±SD                              13.5±2.0                13.9±2.5         0.422
   Hand preference               *N* Right/left/ambidextrous           39/0/1                  37/0/2          0.610
   Medication (MPH)              *N*                                    38/40                    ---            
  *Intervention*                                                                                               
   Body mass index               Mean±SD (range)                16.8±2.8 (12.8--26.3)   17.7±2.1 (14.0--22.5)  0.122
   Percentage compliance         Mean±SD                              92.2±6.9                91.4±6.5         0.573

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; IQ, intelligence quotient; MPH, methylphenidate; RG, reference group of typically developing children.

###### Behavioral and Physiological Measures per Treatment Group

                                                                Baseline                                  Follow-up                                                                                                                  
  ----------------------------------------------- ------------- ------------- ------------- ------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ----------------------------------------
  *Behavior, mean (SD)*                                                                                                                                                                                                              
   CBCL ADHD[a](#t2-fn2){ref-type="fn"}           1.9 (2.1)     2.1 (2.3)     9.0 (3.1)     8.8 (2.1)     2.5 (2.3)                                1.8 (1.6)                                10.1 (2.2)                               7.6 (3.5)
   CBCL Attention Problems                        2.7 (2.8)     2.5 (3.6)     8.9 (3.5)     9.1 (2.5)     3.4 (2.8)[b](#t2-fn3){ref-type="fn"}     2.4 (2.6)[b](#t2-fn3){ref-type="fn"}     10.5 (3.3)[b](#t2-fn3){ref-type="fn"}    7.7 (3.0)[b](#t2-fn3){ref-type="fn"}
   CBCL Rule Breaking                             1.4 (2.2)     0.7 (0.9)     3.8 (2.3)     3.1 (2.8)     1.0 (1.5)                                1.2 (1.8)                                4.1 (2.4)                                2.4 (1.9)
   CBCL Aggressive Behavior                       2.2 (3.7)     2.2 (2.7)     11.0 (5.8)    9.7 (7.2)     1.8 (3.1)                                2.7 (3.2)                                11.8 (5.4)                               7.8 (3.5)
  *Physiology, mean (SD)*                                                                                                                                                                                                            
   %DHA (C22:6 n-3)[c](#t2-fn4){ref-type="fn"}    0.58 (0.23)   0.54 (0.24)   0.67 (0.19)   0.49 (0.13)   0.48 (0.19)[d](#t2-fn5){ref-type="fn"}   0.68 (0.24)[d](#t2-fn5){ref-type="fn"}   0.54 (0.15)[d](#t2-fn5){ref-type="fn"}   0.67 (0.27)[d](#t2-fn5){ref-type="fn"}
   Urine samples HVA[e](#t2-fn6){ref-type="fn"}   1.4 (0.2)     1.4 (0.3)     1.5 (0.3)     1.5 (0.4)     1.3 (0.2)                                1.3 (0.3)                                1.4 (0.3)                                1.5 (0.3)
   EFAQ[f](#t2-fn7){ref-type="fn"}                1.3 (2.3)     0.9 (1.8)     1.8 (1.7)     1.8 (2.1)     1.3 (2.3)                                0.5 (0.9)                                1.6 (2.0)                                1.8 (1.7)

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CBCL, Child Behavior Checklist; DHA, docosahexaenoic acid; EFAQ, Essential Fatty Acids Questionnaire; HVA, homovanillic acid; RG, reference group of typically developing children.

RG^placebo^: 1 baseline, 2 follow-up; RG^active^: 2 follow-up; ADHD^active^: 1 baseline, 6 follow-up.

Main effect of diagnosis and treatment group at follow-up (ANCOVA and LME: *p*≤0.001).

RG^placebo^: 1 baseline, 2 follow-up; RG^active^: 1 baseline, 2 follow-up; ADHD^placebo^: 3 baseline, 1 follow-up; ADHD^active^: 1 baseline, 2 follow-up, 1 both (missing data).

Main effect of treatment group at follow-up (ANCOVA and LME: *p*\<0.001).

RG^placebo^: 2 follow-up; RG^active^: 1 baseline, 2 follow-up; ADHD^active^: 1 baseline, 2 follow-up (missing data).

RG^placebo^: 2 follow-up; RG^active^: 1 follow-up; ADHD^active^: 1 baseline, 1 follow-up (missing data).
